NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Clene Inc. CLNN
7 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 200,000.00
Revenue, FY2025 · full 7-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.2 · Net income -26.2
Compound annual growth
Revenue compounded at −0.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−13086 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -11541.5% · Net -13086.5%
ROE
FY2024 · ROE -1738.4%
Gross margin78.5%
Operating margin-11541.5%
Net margin-13086.5%
Return on assets-115.1%
EBITDAUSD -21.6M
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | · | · | · | −0.16 | −1.10 | −0.93 |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · |
| ROE % | · | −1738.4 | −595.5 | −377.9 | −150.6 | · | · |
| Shares out B | 0.01 | 0.01 | 0.01 | 0.07 | 0.06 | 0.06 | 0.02 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED
Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019